Brilinta instructions for use
Brilint tablets belong to the pharmacological group of drugs - antiplatelet agents and anticoagulants. The drug is used in the treatment of cardiovascular diseases, in which there is a high risk of blood clots inside the vessels, which can lead to a cardiovascular catastrophe in the form of a brain stroke or myocardial infarction.
Release form and composition
Brilin's drug dosage form is coated tablets. The main active ingredient of the drug is ticagrelor, the concentration of which in 1 tablet is 90 mg. Also included excipients:
- Calcium phosphate - 63 mg.
- Mannitol - 126 mg.
- Sodium carboxymethyl starch - 9 mg.
- Magnesium stearate - 3 mg.
- Giproloza - 9 mg.
The composition of the shell covering the tablet includes such excipients:
- Titanium dioxide E 171-1.7 mg.
- Hypromellose 2910-5.6 mg.
- Talc - 1.0 mg.
- Dye iron oxide yellow E172 - 0.1 mg.
- Macrogol 400 - 0.6 mg.
The tablets are packaged in 56 and 112 pieces. The carton pack also contains instructions for use of the drug.
The main active ingredient of Brilint tablets is ticagreol (chemical class - cyclopentyl triazolopyrimidines). It is a selective and reversible antagonist of the P2Y protein, it affects the receptors for ADP (adenazindiphosphate), which prevents ADP-mediated activation and binding (aggregation) of platelets and the formation of an intravascular thrombus. Due to this pharmacological action, Brilint tablets inhibit the formation of blood clots associated with platelet activation and aggregation.
After taking the pill inside the active ingredient of the drug is absorbed into the blood from the cavity of the small intestine. Therapeutic blood concentration is reached in 20-30 minutes after administration, the maximum concentration - in 1.5 hours. The active ingredient is evenly distributed in the body tissues, penetrates through the blood-brain barrier into the brain tissue and through the placental barrier into the body of the developing fetus and into the milk during breastfeeding. Ticagreol is metabolized in the liver cells (hepatocytes), its decay products are excreted with bile. The half-life (duration of elimination from the body of half the dose of the drug) is about 7 hours.
Indications for use
Taking Brilint tablets is indicated to reduce blood clotting and the risk of developing cardiovascular complications such as thrombosis or thromboembolism in such diseases:
- Unstable angina is a deterioration of blood circulation in the myocardium with a high risk of developing a heart attack (death of the heart muscle when a blood clot is blocked by one of the arteries of the heart).
- Myocardial infarction - the death of the heart muscle (myocardium).
- Performing surgery on the coronary vessels of the heart - percutaneous coronary intervention (PCI) or coronary artery bypass surgery (AKV).
As prescribed by a doctor, the drug can be used to reduce the risk of thrombosis in other pathological conditions of the body, including DIC (disseminated intravascular coagulation).
Acceptance of Brilint tablets is contraindicated in certain pathological and physiological conditions of the body, which include:
- Individual intolerance or hypersensitivity to ticagreol or auxiliary components of the drug.
- The presence of active pathological bleeding.
- Hemorrhagic strokes (hemorrhage) of the brain, transferred in the past.
- Reduced functional activity of hepatocytes with the development of moderate or severe liver failure.
- Concomitant use of drugs that have a depressant effect against the enzyme CYP3A4 (clotrimazole, ketoconazole, clarithromycin, ritonavir, nefazodone and atazanavir).
- Children under the age of 18 - the absence of a negative effect of the drug on the child’s body has not been reliably proven.
- Pregnancy at any time and breastfeeding, as there is a risk of negative effects of the drug on the developing fetus.
In the absence of contraindications, you must make sure before the use of Brilint tablets.
Dosage and administration
Brilint tablets are taken entirely inside, without chewing, and regardless of the meal. After taking the pill, wash it down with a sufficient amount of liquid. The dosage of the drug is 90 mg (1 tablet) per day, take a pill at the same time. Begin a course of treatment with a double dose (180 mg) on the first day, then proceed to a constant intake of 90 mg. The course of treatment is on average 12 months. Be sure to take acetylsalicylic acid as an additional antiplatelet agent in parallel with Brilint tablets. In case of missing a Brillint tablet, it is resumed the next day at the usual time of admission. It is necessary to avoid discontinuing the drug, as this may lead to a significant increase in the risk of thrombosis (only the doctor cancels the drug, in case of clinical necessity).
The main side effect of Brilint tablets is an excessive decrease in blood coagulation with the development of various types of pathological bleeding - internal bleeding in the stroma or parenchyma of organs, post-traumatic bleeding, development of hematomas and bruises, especially after various intramuscular injections. Sometimes it is possible to develop an allergic reaction to ticagreol or drug auxiliaries in the form of a skin rash and itching. More rarely, a more severe allergic reaction in the form of angioedema of the Quincke edema (a characteristic rash and swelling of the skin, resembling a stinging nettle) develops. It is also possible the development of anaphylactic shock (marked reduction of systemic arterial pressure and multiple organ failure). On the part of the digestive system, nausea and vomiting are rarely observed. If side effects occur, the doctor will decide on the cancellation of the drug.
Before you start taking Brilint tablets, you must carefully study the instructions to the drug. During the use of tablets, special care must be taken with regard to injury, as this can lead to severe bleeding. Also, while taking the drug, there remains a high risk of bleeding after a percutaneous coronary intervention or coronary artery bypass surgery. The drug does not affect the concentration of attention or the speed of psychomotor reactions. Nevertheless, it is recommended to refuse to perform any activity related to the need for increased concentration of attention or speed of psychomotor reactions (working at height, driving a car or other transport). In pharmacies, the drug is released only by prescription. In case of any questions or doubts regarding his reception, it is necessary to consult a doctor.
If the recommended therapeutic dose is exceeded, nausea, flatulence (gas accumulation in the intestine) develops, the risk of bleeding and impairment of the heart increase. In this case, the gastric, intestinal lavage and symptomatic therapy is performed. There is no specific antidote to the active ingredient of the drug.
Analogs of Brilint tablets regarding therapeutic action are Clopidogrel, Aspigrel. Acetylsalicylic acid-based drugs that are used in cardiology as antiplatelet agents - Cardiomagnyl, Aspecard, Aspirin-Cardio have a similar effect, but an excellent mechanism of action.
Terms and conditions of storage
The shelf life of Brilint tablets is 2 years from the date of manufacture. It is necessary to store the drug in a dark, dry place at an air temperature not higher than + 30 ° C. Keep away from children.
Brilint tablets 90mg, 56 pcs. - 4600-5300 rub.